ArticleClinical science (London, England : 1979)2020

Melanocortin therapy ameliorates podocytopathy and proteinuria in experimental focal segmental glomerulosclerosis involving a podocyte specific non-MC1R-mediated melanocortinergic signaling.

Yingjin Qiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.